Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
about
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomesProgressive multifocal leukoencephalopathy: current treatment options and future perspectivesStratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupNeuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesNew insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathyNatalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosisNatalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Neurologic indications for therapeutic plasma exchange: 2013 update.Best practice in the use of natalizumab in multiple sclerosis.PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.TB-IRIS: Proteomic analysis of in vitro PBMC responses to Mycobacterium tuberculosis and response modulation by dexamethasoneThe use of natalizumab for multiple sclerosisTreating multiple sclerosis with monoclonal antibodies: a 2013 update.Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Metabolic profile of PML lesions in patients with and without IRIS: an observational study7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case studyCurrent and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.PML-IRIS in a patient treated with brentuximabNatalizumab therapy for multiple sclerosisNew and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathyComplications of immunosuppressive/immunomodulatory therapy in neurological diseases.Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.Monoclonal antibodies as disease modifying therapy in multiple sclerosis.Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.The management of pediatric multiple sclerosis.Medications and therapeutic apheresis procedures: are we doing our best?The human JC polyomavirus (JCPyV): virological background and clinical implications.Metabolic and safety issues for multiple sclerosis pharmacotherapy--opportunities for personalised medicine.Progressive multifocal leukoencephalopathy therapyImmune reconstitution inflammatory syndrome mimicking progressive multifocal leucoencephalopathy in a multiple sclerosis patient treated with natalizumab: a case report and review of the literature
P2860
Q26776234-7C9A55A2-B275-4F0B-9AD3-5031AC7D7CFAQ26776236-F23A788E-4537-4DB0-ACE4-42BD078B8908Q26780412-34953605-9E4C-4A92-BC26-43CA311AEAF7Q26781389-4F865EB7-A4C6-4E07-8EF6-B57D835B64EEQ26822247-903EF29C-BFD9-4FA4-86E3-99EFC6A56CC2Q28484467-165B39B6-F5C5-45EB-8F00-3DDA5A241511Q28555138-6A4B9113-530A-45FA-9359-705C0E91DB6DQ30276550-30143540-D5C9-4548-8478-9BFF2376089EQ30458271-FF004BE2-66D0-43B0-9D49-CD74FF66E58DQ30597618-210B1146-FC17-4913-9E1B-75D7B66ECD08Q30613846-E8C684F1-CF66-47DA-BD88-5514180E32DBQ30815289-54368989-D015-463E-AB50-5FD5A631AC1FQ33732480-9E70B050-F489-4D6B-A9F4-D7A5BD8FFE66Q33879159-B2123937-374B-4EA9-A30A-BB35B25AC5E1Q34330211-95AA69CD-8560-4C0F-90B9-8DAE53F03267Q34365360-E59C5583-B2D4-44B3-BA2A-BC8CF7D82AE3Q34505467-18401A6B-6D32-47E1-B2A1-52B09BEAF61EQ35675602-B5078573-D024-4D7A-88A0-CC21FE0D9921Q35701501-F62336A3-5405-464E-AEFB-49DD930AEEA1Q35825914-E93036C1-9929-49E2-8172-2601C6D0462CQ36198630-EFEEB45E-C95B-4FE9-8528-DF630B55929CQ36242324-55A36B3F-EB98-4B6C-A420-A02B63584545Q36352813-19CC3FED-39B5-40A5-A3D4-F83687165D25Q36439197-EF6C3F7A-1489-448E-85A4-5AD64366F4BBQ36568666-C61B5F4C-5ED1-468B-9526-DEA6D64CD387Q36748702-3A1F49BB-46CD-4FF2-827B-DE58A7D69B1EQ36764988-1EDE9E91-E8B4-4B00-ACD1-8A31C88BC3E0Q37013065-850A1195-34DB-47C3-9DEB-46617C7702E8Q37206687-BEBBFEB6-20FC-4485-8972-589E800A46F7Q37313729-6DE82BAB-BD15-44FC-83D6-E96EFAD75F32Q37475542-808CBC13-1BCB-4150-978D-F8C774620E07Q37653126-1767C8CD-E797-4819-BFC7-AAA4AF94D006Q37668086-D2D1D0DC-F607-4614-9727-578E13B2E9B5Q37980042-67AC6D5B-6360-462C-96D1-00BFDCB19CF3Q38036853-583C13AB-7010-40CC-88CF-0E61C9A423BAQ38082738-C8BB182F-5AFD-4257-BF69-014A4C45AE8FQ38115572-8562ABA2-6236-40B6-A9DB-8D5D8A370AADQ38218692-CA86198B-F231-4397-99AB-8577BAD0F4FDQ38250227-B7AC1827-1DD2-40A9-B441-8357CB6ACAF8Q38264914-601C87FD-DC23-49FC-A6FD-6965068CEBA7
P2860
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@ast
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@en
type
label
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@ast
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@en
prefLabel
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@ast
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@en
P2093
P2860
P1433
P1476
Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
@en
P2093
P2860
P304
P356
10.1212/WNL.0B013E31822E55E7
P407
P577
2011-08-10T00:00:00Z